Lv1
50 积分 2024-06-29 加入
Safety and efficacy of the anti-TL1A monoclonal antibody tulisokibart for Crohn's disease: a phase 2a induction trial
14天前
已完结
Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial
14天前
已完结
Intestinal organ chips for disease modelling and personalized medicine
2个月前
已完结
Heterogeneity of the intestinal mononuclear phagocyte compartment in health and inflammatory bowel disease
2个月前
已完结
Failure to Achieve Target Drug Concentrations During Induction and Not HLA-DQA1∗05 Carriage Is Associated With Antidrug Antibody Formation in Patients With Inflammatory Bowel Disease
2个月前
已完结
Immunogenicity of Therapeutic Antibodies Used for Inflammatory Bowel Disease: Treatment and Clinical Considerations
3个月前
已完结
Successful Management of Oral Manifestations of Behcet’s Disease and Sjogren’s Disease Using Washed Microbiota Transplantation: A Case Report
9个月前
已关闭
皖公网安备34019202002308
